Patent Portfolio
13 U.S. Provisional Patent Applications Filed — Patent Pending
Provisional Applications
Filed Patents
U.S. Prov. App. No. 64/100,396
Provisional — ActiveFiled
June 27, 2026
Core Simulation Architecture & Clinical Applications
Core Diagnostic Biophysical Model
Covers core simulation architecture, irreversibility prediction algorithms, and sRAGE-based biomarker strategies.
Key Coverage Areas
U.S. Prov. App. No. 64/101,014
Provisional — ActiveFiled
June 29, 2026
Foundational Numerical Methods
Variational Lagrangian Discretization Method
Covers numerical methods enabling resolution-invariant tissue simulation across multi-scale grids.
Key Coverage Areas
U.S. Prov. App. No. 64/109,676
Provisional — ActiveFiled
July 11, 2026
Symplectic Numerical Integration
Symplectic Integrators for Hybrid Agent-Based Systems
Covers symplectic integration methods applied to biological tissue simulation, preserving Hamiltonian structure and long-term energy stability in multi-cellular agent-based models.
Key Coverage Areas
U.S. Prov. App. No. 64/109,679
Provisional — ActiveFiled
July 11, 2026
Neural Operator Acceleration
Physics-Informed Neural Operators for Simulation Acceleration
Covers the application of neural operator architectures to accelerate solution of partial differential equations governing substrate transport and signaling in biological tissue digital twins.
Key Coverage Areas
U.S. Prov. App. No. 64/109,692
Provisional — ActiveFiled
July 11, 2026
Boundary Stability & Limiters
Non-linear Boundary Flux Limiters in Continuum Tissue Fluid Coupling
Covers boundary limiter techniques that enforce physical constraints at tissue boundaries in agent-based simulations, preventing non-physical solutions and ensuring numerical stability at lobule interfaces.
Key Coverage Areas
U.S. Prov. App. No. 64/109,727
Provisional — ActiveFiled
July 11, 2026
AGE-RAGE Feedback Loop Architecture
RAGE-sRAGE Stoichiometric Perpetuation Loop Model
Covers the computational architecture of the closed AGE-RAGE positive feedback loop — including receptor binding kinetics, NF-κB pathway activation, and HSC state transitions — as implemented in the hepatic fibrosis digital twin.
Key Coverage Areas
U.S. Prov. App. No. 64/109,732
Provisional — ActiveFiled
July 11, 2026
Cellular State Machine Architecture
Stoichiometric Biological State Machinery for Parenchymal Remodeling
Covers the state machine architecture governing multi-phenotype cellular agents — including hepatocytes, hepatic stellate cells, Kupffer cells, and NK cells — and their state transition logic within the hepatic fibrosis simulation framework.
Key Coverage Areas
U.S. Prov. App. No. 64/109,734
Provisional — ActiveFiled
July 11, 2026
Percolation Theory & Irreversibility
Collagen Percolation Staging and Irreversibility Boundaries
Covers the application of percolation theory to define and detect the structural irreversibility threshold in hepatic fibrosis — where collagen fiber networks transition from isolated degradable fibers to a connected, mechanically stable, MMP-resistant scaffold.
Key Coverage Areas
U.S. Prov. App. No. 64/109,854
Provisional — ActiveFiled
July 12, 2026
Multi-Scale Simulation Coupling
Multi-Scale Variational Discretization of Coupled Agent-Field Systems
Covers methods for coupling molecular-scale signaling dynamics, cellular-scale agent behavior, and tissue-scale structural mechanics within a unified multi-scale hepatic digital twin framework.
Key Coverage Areas
U.S. Prov. App. No. 64/109,858
Provisional — ActiveFiled
July 12, 2026
Deformable Lattice Boundary Tracking
Variational Boundary Tracking in Deformable Biological Lattices
Covers variational methods for tracking and enforcing boundary conditions in deformable biological lattice structures, enabling accurate simulation of tissue remodeling and morphological change during fibrosis progression.
Key Coverage Areas
U.S. Prov. App. No. 64/109,860
Provisional — ActiveFiled
July 12, 2026
Active Non-Equilibrium Matter Physics
Variational Modeling of Active Non-Equilibrium Dissipative Matter
Covers variational formulations for modeling active, non-equilibrium, dissipative matter — capturing self-propulsion, energy dissipation, and collective behavior of motile cell populations in fibrosis-driven tissue remodeling.
Key Coverage Areas
U.S. Prov. App. No. 64/109,865
Provisional — ActiveFiled
July 12, 2026
Automatic Differentiation & Variational Compilation
Automatic Differentiation and Compilation of Variational Biophysical Manifolds
Covers automatic differentiation and compilation techniques applied to variational biophysical manifolds — enabling gradient-based calibration and symbolic compilation of simulation parameters against clinical endpoint data.
Key Coverage Areas
U.S. Prov. App. — Provisional Filed
Provisional — ActiveFiled
July 22, 2026
Adaptive Capacity Control Architecture
Etiology- and Local-State-Adaptive Capacity Control
Covers etiology-adaptive capacity gating (L7) and per-voxel survival compensation (L8).
Key Coverage Areas
IP Strategy
What We Protect
Our patent strategy covers both the clinical application layer — how the simulation predicts irreversibility and guides treatment — and the foundational computational layer that makes high-fidelity tissue simulation tractable. Together, these patents protect the full stack from numerical methods to clinical decision support.
Simulation Architecture
The spatial, GPU-accelerated 3D agent-based model structure and its 14-subsystem coupling methodology.
Irreversibility Prediction
Algorithms for detecting stage-dependent irreversibility thresholds as emergent properties — without explicit stage-gating rules.
sRAGE Biomarker Strategy
Methods for using sRAGE trajectory divergence as a clinically measurable indicator of the reversibility transition point.
Numerical Methods
Variational Lagrangian discretization enabling resolution-invariant simulation — scalable across tissue types and disease states.
Partnership Opportunities
Licensing & Co-Development
We are actively seeking partners for licensing, co-development, and clinical validation. Our technology is ready for integration into pharmaceutical development pipelines, clinical research platforms, and digital health applications.
Pharmaceutical Licensing
License the simulation platform to support RAGE/AGE-targeted drug development — identify optimal patient populations, predict responder profiles, and design stage-stratified clinical trials.
Clinical Research Co-Development
Partner with clinical researchers to validate sRAGE biomarker predictions against longitudinal patient cohorts — generating the clinical evidence base for regulatory submissions.
Digital Health Integration
Integrate the digital-twin simulation engine into precision medicine platforms, EHR-connected decision support tools, or patient monitoring systems.
Ready to explore a partnership?
All licensing inquiries are handled directly by Wayne Eskridge, Founder.